NCT04022980 2025-12-30
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
Clinical Trials
10 trialsNCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT02631746 2025-03-14
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03229278 2023-12-06
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03580408 2022-08-19
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02038946 2022-01-04
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Bristol-Myers Squibb
Phase 2 Completed
NCT02857426 2021-12-23
CheckMate 647
Bristol-Myers Squibb
Phase 2 Completed
NCT04439214 2021-04-06
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02518958 2019-11-18
PRIMETIME
EpicentRx, Inc.
Phase 1 Completed